Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

818.93 -10.81 (-1.30%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
This Is What Whales Are Betting On Eli Lilly and Co
Via Benzinga
Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs 
Via MarketBeat
2 Top Stocks That Could Make You Richer in 2024
Here are a couple of great ideas on where to invest your money today. 
Via The Motley Fool
3 Super-Safe Dividend Stocks That Have Been Making Recurring Payments for 130+ Years
These stocks have rock-solid businesses and they have impressive track records for paying dividends. 
Via The Motley Fool
3 No-Brainer Stocks to Buy in May
These great stocks are great picks for investors as spring winds down. 
Via The Motley Fool
Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making
Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro. 
Via The Motley Fool
Comparative Study: Eli Lilly and Co And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
Here's Why Eli Lilly Stock Remains a Screaming Buy
The biggest healthcare company in the world could grow much larger over the next decade. 
Via The Motley Fool
Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?
The anti-obesity medication stock is way up, and there could be more fuel in the tank. 
Via The Motley Fool
Why Amgen Stock Zoomed Nearly 12% Higher Today
The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop. 
Via The Motley Fool
3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030
These under-the-radar stocks have the potential to reach a $1 trillion valuation by 2030 as they gain momentum in their respective industries. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
What 23 Analyst Ratings Have To Say About Eli Lilly and Co
Via Benzinga
Wage Growth Slows – Stock Market Celebrates, Five Real Reasons Apple Is Running Up
To gain an edge, this is what you need to know today. 
Via Benzinga
1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $892. Is It a Buy?
The company seems to be going from strength to strength lately. 
Via The Motley Fool
Weigh Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
Reduced prices on Wegovy and Mounjaro at British pharmacies amid growing competition. Simple Online Pharmacy slashes Mounjaro starter doses to £149 from £179, catering to high demand. 
Via Benzinga
3 Stocks Gunning for Trillion-Dollar Status: The Players to Own Now
These three stocks closing in on trillion-dollar valuations are ready to stand shoulder-to-shoulder with other industry giants. 
Via InvestorPlace
3 Staples Stocks to Cushion Lower Consumer Sentiment
Three stocks in the consumer staples sector could come to save investor portfolios from potential underperformance following sentiment contractions 
Via MarketBeat
Topics Economy
Exposures Economy
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly. 
Via Benzinga
Q1 Earnings Seasons Picks & Pans: The 4 Biggest Stock Winners (and 3 Losers)
Investors should take note of this earnings season winners and losers to see how stocks they own are doing now Q1 results have been released. 
Via InvestorPlace
Eli Lilly 'On Its Way' To $1 Trillion Market Cap, Analysts Say: It's A 'Have' In A Sea Of 'Have Nots'
Eli Lilly's first-quarter report shows a revenue surge of 26%, beating EPS expectations. Analysts maintain a bullish outlook. 
Via Benzinga
ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook
Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest... 
Via Talk Markets
Topics ETFs
Profit from the Panic: 3 Stocks to Pounce on When They Become Steals
We love it when our favorite clothes go on sale, so when the market offers us a deal, these are the stocks to buy on dips. 
Via InvestorPlace
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Consumer Stocks.
While some retail companies are still thriving, investors would be smart to steer clear of these consumer stocks to avoid. 
Via InvestorPlace
Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge
A slip in the market could give investors a rare opportunity to get some top biotech stocks to buy at a considerable discount. 
Via InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology. 
Via InvestorPlace
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations
Pfizer reports Q1 results: adjusted EPS beats estimates, driven by revenue growth. Significant declines in Comirnaty and Paxlovid revenues countered by operational gains. Company announces plans for... 
Via Benzinga
Exposures COVID-19
Nearly 50% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 4 Stocks
The billionaire's family fund is surprisingly concentrated. 
Via The Motley Fool
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.